Seth Loring Harrison
CIK 1404955 · last filed 2026-07-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$504.38M
Companies
4
Total Filings
70
Lifetime Open-Market Net
-$52.02M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STOK | Director | 17,161,713 | $29.39 | $504.38M | $39.63M | 11 | 2026-07-17 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | $14.28M | 13 | 2025-12-09 |
| HeartWare International, Inc. (HTWR) Delisted | Director | 0 | — | — | -$111.36M | 31 | 2016-08-24 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Director | 902,753 | — | — | $5.44M | 3 | 2016-06-16 |
Recent Filings · Page 2 of 7
70 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-11-01 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −44,103 | -$1.78M | EDGAR |
| 2022-10-27 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −285,487 | -$12.19M | EDGAR |
| 2022-06-08 | STOK | Grant (A) | — | $0 | EDGAR |
| 2022-06-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-25 | STOK | Grant (A) | — | $0 | EDGAR |
| 2021-06-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-11-25 | STOK | Buy (P) | +375,000 | $14.62M | EDGAR |
| 2020-07-14 | Akero Therapeutics, Inc. (AKRO) Delisted | Buy (P) | +415,000 | $14.94M | EDGAR |
| 2020-06-05 | STOK | Grant (A) | — | $0 | EDGAR |
| 2020-06-02 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.